Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | AKT1 | P31749 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2487493 | 0.87 | LMNA (0.46) | LMNAPOLBCA12CA1CA7 | |
| SCHEMBL6954162 | 0.83 | STAT3 (0.39) | LMNAPOLBHSP90AA1HSP90AB1BRD9 | |
| SCHEMBL16307600 | 0.83 | CYP17A1 (0.40) | METAP1 | |
| SCHEMBL5757395 | 0.81 | POLB (0.47) | LMNAPOLBRXFP1AKT1BRD9 | |
| SCHEMBL1772002 | 0.81 | LMNA (0.47) | LMNAPOLBCA12CA1CA7 | |
| SCHEMBL18940331 | 0.80 | POLB (0.47) | POLBALDH1A1 | |
| SCHEMBL11369 | 0.80 | SLC6A2 (0.42) | LMNAPOLBCA12CA1CA7 | |
| SCHEMBL27738875 | 0.80 | POLB (0.40) | LMNAPOLBCA12CA1CA7 | |
| SCHEMBL14088915 | 0.80 | AKT1 (0.46) | LMNAPOLBCA12CA1CA7 | |
| SCHEMBL29991524 | 0.79 | POLB (0.50) | LMNAPOLBRXFP1CTSLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635697-B2 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION (US) | 2009-12-22 | — | — | US | disclosed |
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | SCHERING CORPORATION | 2006-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211706-A1 | Farnesyl protein transferase inhibitors and methods for treating proliferative diseases | FNTB, FNTA, FDPS | LMNA 2619/4885POLB 1803/4885CA12 4315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.